Daiichi Vows Action As $41.8m Patent Decision Favors Seagen

‘039 Claims Also Now Under Review

A US jury decision in a long-running ADC patent dispute between Seagen and Daiichi Sankyo has found in favor of the US firm. But Daiichi has vowed to challenge the outcome while its motion to question the validity of the original patent on which the case is based has also just been granted, meaning the final impact remains uncertain.

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.
New legal decision as breast cancer rivals set for market battle • Source: Shutterstock

A jury in the US District Court of Eastern District of Texas decided on 8 April that the sale in the US of Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan; DS-8201) infringes Seagen Inc. ’s US patent 10,808,039.

The decision awarded damages of $41.82m for past infringement in the period leading up to trial and found there was...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.